312 related articles for article (PubMed ID: 23807662)
1. SNAI1 protein expression is an independent negative prognosticator in muscle-invasive bladder cancer.
Keck B; Wach S; Goebell PJ; Kunath F; Bertz S; Lehmann J; Stöckle M; Taubert H; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Oct; 20(11):3669-74. PubMed ID: 23807662
[TBL] [Abstract][Full Text] [Related]
2. The expression profile of p14, p53 and p21 in tumour cells is associated with disease-specific survival and the outcome of postoperative chemotherapy treatment in muscle-invasive bladder cancer.
Aljabery F; Shabo I; Gimm O; Jahnson S; Olsson H
Urol Oncol; 2018 Dec; 36(12):530.e7-530.e18. PubMed ID: 30539751
[TBL] [Abstract][Full Text] [Related]
3. Copper Transporter-CTR1 Expression and Pathological Outcomes in Platinum-treated Muscle-invasive Bladder Cancer Patients.
Kilari D; Iczkowski KA; Pandya C; Robin AJ; Messing EM; Guancial E; Kim ES
Anticancer Res; 2016 Feb; 36(2):495-501. PubMed ID: 26851002
[TBL] [Abstract][Full Text] [Related]
4. Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.
Patry G; Hovington H; Larue H; Harel F; Fradet Y; Lacombe L
Int J Cancer; 2008 Apr; 122(7):1592-7. PubMed ID: 18058798
[TBL] [Abstract][Full Text] [Related]
5. Induction Chemotherapy Followed by Surgery Versus Upfront Radical Cystectomy in Patients With Clinically Node-positive Muscle-invasive Bladder Cancer.
Pak S; You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Kim CS; Ahn H
Clin Genitourin Cancer; 2019 Jun; 17(3):e420-e428. PubMed ID: 30713014
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer.
Jiang DM; Jiang H; Chung PWM; Zlotta AR; Fleshner NE; Bristow RG; Berlin A; Kulkarni GS; Alimohamed NS; Lo G; Sridhar SS
Clin Genitourin Cancer; 2019 Feb; 17(1):38-45. PubMed ID: 30686350
[TBL] [Abstract][Full Text] [Related]
7. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
8. A reported 20-gene expression signature to predict lymph node-positive disease at radical cystectomy for muscle-invasive bladder cancer is clinically not applicable.
van Kessel KE; van de Werken HJ; Lurkin I; Ziel-van der Made AC; Zwarthoff EC; Boormans JL
PLoS One; 2017; 12(3):e0174039. PubMed ID: 28319171
[TBL] [Abstract][Full Text] [Related]
9. Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study.
Hemdan T; Malmström PU; Jahnson S; Segersten U
J Urol; 2015 Dec; 194(6):1575-81. PubMed ID: 26119672
[TBL] [Abstract][Full Text] [Related]
10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
[TBL] [Abstract][Full Text] [Related]
11. EORTC progression score identifies patients at high risk of cancer-specific mortality after radical cystectomy for secondary muscle-invasive bladder cancer.
May M; Burger M; Brookman-May S; Stief CG; Fritsche HM; Roigas J; Zacharias M; Bader M; Mandel P; Gilfrich C; Seitz M; Tilki D
Clin Genitourin Cancer; 2014 Aug; 12(4):278-86. PubMed ID: 24331576
[TBL] [Abstract][Full Text] [Related]
12. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer.
Kitagawa Y; Izumi K; Miwa S; Kadono Y; Konaka H; Mizokami A; Namiki M
Anticancer Res; 2013 Oct; 33(10):4497-503. PubMed ID: 24123021
[TBL] [Abstract][Full Text] [Related]
13. Nuclear E-cadherin expression is associated with the loss of membranous E-cadherin, plasmacytoid differentiation and reduced overall survival in urothelial carcinoma of the bladder.
Keck B; Wach S; Kunath F; Bertz S; Taubert H; Lehmann J; Stöckle M; Wullich B; Hartmann A
Ann Surg Oncol; 2013 Jul; 20(7):2440-5. PubMed ID: 23108554
[TBL] [Abstract][Full Text] [Related]
14. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma.
Moschini M; Suardi N; Pellucchi F; Rocchini L; La Croce G; Capitanio U; Briganti A; Damiano R; Montorsi F; Colombo R
Anticancer Res; 2014 Jun; 34(6):3225-30. PubMed ID: 24922698
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience.
Efstathiou JA; Spiegel DY; Shipley WU; Heney NM; Kaufman DS; Niemierko A; Coen JJ; Skowronski RY; Paly JJ; McGovern FJ; Zietman AL
Eur Urol; 2012 Apr; 61(4):705-11. PubMed ID: 22101114
[TBL] [Abstract][Full Text] [Related]
16. B4GALT1 expression predicts prognosis and adjuvant chemotherapy benefits in muscle-invasive bladder cancer patients.
Xie H; Zhu Y; Zhang J; Liu Z; Fu H; Cao Y; Li G; Shen Y; Dai B; Xu J; Ye D
BMC Cancer; 2018 May; 18(1):590. PubMed ID: 29793447
[TBL] [Abstract][Full Text] [Related]
17. [Multivariate evaluation of survival factors and postoperative adjuvant chemotherapy in patients with bladder cancer treated by radical cystectomy].
Takashi M; Murase T; Aota Y; Nagai T; Kinjo T; Sabashi M; Shimoji T; Miyake K; Hamajma N; Mizuno S
Hinyokika Kiyo; 1988 Aug; 34(8):1377-81. PubMed ID: 2461643
[TBL] [Abstract][Full Text] [Related]
18. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy.
Lotan Y; Bagrodia A; Passoni N; Rachakonda V; Kapur P; Arriaga Y; Bolenz C; Margulis V; Raj GV; Sagalowsky AI; Shariat SF
Eur Urol; 2013 Sep; 64(3):465-71. PubMed ID: 23571005
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
20. The role of neoadjuvant chemotherapy, lymph node dissection, and treatment delay in patients with muscle-invasive bladder cancer undergoing partial cystectomy.
Lenis AT; Fero KE; Ojeaburu L; Lec PM; Golla V; Brisbane W; Leapman MS; Chamie K
Urol Oncol; 2021 Aug; 39(8):496.e17-496.e24. PubMed ID: 33640225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
